Trial Summary
What is the purpose of this trial?This trial studies using stronger doses in fewer sessions to treat cervical or endometrial cancer. It aims to kill more cancer cells and reduce side effects.
Eligibility Criteria
This trial is for adults over 18 with cervical or endometrial cancer, who've had a hysterectomy and are in good health post previous cancer treatments. They must be able to consent, have an ECOG status of <=2, non-metastatic disease, and a life expectancy over 2 years. Those with recent other cancers or certain medical conditions can't join.Inclusion Criteria
My doctor decides if I need chemotherapy along with radiation.
I had a hysterectomy for cervical or endometrial cancer.
I can take care of myself but might not be able to do heavy physical work.
+6 more
Exclusion Criteria
It's been over 16 weeks since my hysterectomy, but I had chemotherapy before starting radiotherapy.
I haven't been diagnosed with any cancer other than skin, breast, bladder, or cervical cancers in the last 2 years.
Medical, psychiatric, cognitive, or other conditions in the opinion of the investigator that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study
+2 more
Participant Groups
The study tests hypo-fractionated radiotherapy for cervical/endometrial cancer treatment. This method uses higher radiation doses given in a shorter time frame than traditional therapy, aiming to kill more tumor cells while reducing side effects.
1Treatment groups
Experimental Treatment
Group I: Treatment (hypo-fractionated radiotherapy)Experimental Treatment1 Intervention
Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity.
Hypofractionated Radiation Therapy is already approved in United States, European Union, Canada for the following indications:
🇺🇸 Approved in United States as Hypofractionated Radiotherapy for:
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
🇪🇺 Approved in European Union as Hypofractionated Radiotherapy for:
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
🇨🇦 Approved in Canada as Hypofractionated Radiotherapy for:
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Huntsman Cancer Institute/University of UtahSalt Lake City, UT
Loading ...
Who Is Running the Clinical Trial?
University of UtahLead Sponsor
National Cancer Institute (NCI)Collaborator